EARNING RECAP

Sarepta Therapeutics Inc

#SRPT 2018 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q2 (71c) est. (89c) $73.5M est. $71.59M +9.87% ($132.96 closing) $138.50 $124.50
Q1 (28c) vs (32) $64.6M vs $64.8m +14.81% ($89.75 closing) $90.99 $76.20 in pact with Myonexus for advancement of gene therapy programs
#SRPT 2017 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 (28c) est. (32c) $57.3M est. $56.48M +9.41% ($67.96 closing) $68.68 $59.51
Q3 (78c) vs (85c) $46M vs. $40.77M -1.49% ($47.64 closing) $49.74 $46.07 Guides FY '17 revenue $150M-$155M from$139.45M
Q2 46c vs 91c EST $35.0M vs. $22.88M +7% ($40.93 closing) $39.56 $43.69 Raised guidance and stock pop over 10%
Q1 60c vs 30c est $16.30M vs $13.86m +4.44% ($36.26 closing) $39.34 $35.20 -3.23% @ $33.60 AH. CEO says focused on momentum of the EXONDYS 51 launch. CEO steppings down lead to speculation reversal.

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.